Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Teva
Chinese Patent Office
Julphar
Baxter
Deloitte
Mallinckrodt
Queensland Health
QuintilesIMS
Johnson and Johnson

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,067,148

« Back to Dashboard

Which drugs does patent 7,067,148 protect, and when does it expire?

Patent 7,067,148 protects LEVOXYL and is included in one NDA.

This patent has twenty-six patent family members in nine countries.
Summary for Patent: 7,067,148
Title:Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
Abstract:A pharmaceutical composition with .beta.-sheet microcrystalline cellulose with improved potency life and methods of preparation therefor. Improved thyroid hormone pharmaceutical compositions comprising 50 weight % or more of .beta.-sheet microcrystalline cellulose.
Inventor(s): Franz; G. Andrew (St. Louis, MO), Strauss; Elaine A. (Seminole, FL), DiMenna; Philip A. (St. Petersburg, FL), Gemma; Rocco L. (Dover, OH)
Assignee: King Pharmaceutical Research & Development, Inc. (Cary, NC)
Application Number:10/076,999
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 7,067,148

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-001 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-002 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-003 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-004 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-005 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-006 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-007 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-008 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-009 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-010 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,067,148

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,555,581 Levothyroxine compositions and methods ➤ Sign Up
7,101,569 Methods of administering levothyroxine pharmaceutical compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,067,148

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002240394 ➤ Sign Up
Australia 2002258397 ➤ Sign Up
Australia 2002332507 ➤ Sign Up
Australia 2002341555 ➤ Sign Up
Australia 2002362468 ➤ Sign Up
Brazil 0207297 ➤ Sign Up
Brazil 0207299 ➤ Sign Up
Canada 2438641 ➤ Sign Up
Canada 2438907 ➤ Sign Up
Canada 2440190 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Dow
Chinese Patent Office
Queensland Health
AstraZeneca
Federal Trade Commission
Cantor Fitzgerald
QuintilesIMS
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot